Barclays lowered the firm’s price target on Surgery Partners to $51 from $56 and keeps an Overweight rating on the shares post the Q2 results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGRY:
- Surgery Partners, Inc. Announces Second Quarter 2023 Results
- Surgery Partners sees FY23 adjusted EBITDA greater than $435M
- Surgery Partners reports Q2 adjusted EPS 28c, consensus 8c
- Surgery Partners Inc. (SGRY) Q2 Earnings Cheat Sheet
- Surgery Partners, Inc. Announces Second Quarter 2023 Earnings Release Date and Conference Call Details